GlassScriptPhysician profile
Peter S Mccauley
NPI 1629189113
$3,641.83
in general payments reported to CMS, 2019-2025
26 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $369 · 2021: $469 · 2022: $755 · 2023: $331 · 2024: $533 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Education: $2.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.07 |
| Education | $2.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $555.12 | 2019-2023 | Velphoro |
| Amgen INC. | $450.37 | 2019-2025 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $333.43 | 2021-2024 | Benlysta, Jesduvroq |
| Astrazeneca Pharmaceuticals LP | $270.93 | 2021-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $263.21 | 2020-2025 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $224.76 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $197.36 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $184.40 | 2019-2022 | |
| Akebia Therapeutics INC | $145.50 | 2021-2025 | Vafseo |
| Vifor Pharma, INC. | $110.79 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $109.44 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $95.74 | 2021-2025 | |
| Travere Therapeutics, INC. | $92.56 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $83.72 | 2022-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $74.19 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $66.99 | 2025 | Ozempic, Wegovy |
| Daiichi Sankyo INC. | $56.50 | 2021-2022 | |
| Ardelyx, INC. | $47.35 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $46.55 | 2024-2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $45.60 | 2019 | |
| Scpharmaceuticals INC. | $43.23 | 2025 | |
| Aurinia Pharma U.S., INC. | $40.30 | 2022-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $40.25 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $31.50 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $17.84 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.20 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mccauley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.